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Fotemustine is a clinically used DNA-alkylating 2-chloro-
ethyl-substituted N-nitrosourea, which sometimes shows
signs of haematotoxicity and reversible liver and renal
toxicity as toxic side-effects. Mechanistic data on these
side-effects are scarce and incomplete. In this study, firstly
the cytotoxicity of fotemustine in freshly isolated rat hepato-
cytes was investigated and secondly the metabolism of
fotemustine and possible mechanisms involved in the
observed cytotoxicity. Fotemustine caused concentration-
and time-dependent cytotoxic effects in rat hepatocytes.
Extensive GSH-depletion and formation of GSSG were
first observed, followed by lipid peroxidation and finally
by cell death measured as LDH-leakage. 2-Chloroethyl
analogues of fotemustine, which in contrast to fotemustine
have no carbamoylating potency, were not toxic to rat
hepatocytes. The data suggest that the cytotoxicity of
fotemustine is resulting from its reactive decomposition
product, DEP-isocyanate. GSH-conjugation of DEP-iso-
cyanate was shown to protect against the cytotoxicity of
fotemustine, however, only temporary and not completely.
Synthetical DEP-SG, the GSH-conjugate of DEP-iso-
cyanate, was also toxic to rat hepatocytes, albeit to a
significantly lesser extent than fotemustine. In rat liver
microsomes, no fotemustine-induced LPO was observed,
suggesting that reactive decomposition products of fotemus-
tine do not directly cause peroxidation of cellular mem-
branes. Fotemustine did not affect the antioxidant enzymes
superoxide dismutase, catalase, GSH-peroxidase, GSSG-
reductase and GSH S-transferases. Thus, direct effects on
•Abbreviations: I, [l-(2-oxo imidazohdine-l-yl)ethyl] diethylphosphonate;
II, (l-aminoethyl)diethy!phosphonate; BCNU, l,3-bis(2-chloroethyl)-l-nitro-
sourea; BSA, bovine serum albumin; CCNU, l-(2-chloroethyl)-3-cyclohexyl-
1-nitrosourea; CENU, 2-chloroethyl JV-nitrosourea; CNC-1: 2-chloroethyl
nitrosocarbamoyl alaninemethylamide; CNC-2, 2-chloroethyl nitrosocarba-
moyl glycylglycine; CNC-3, 2-chloroethyl nitrosocarbamoyl alanylalanine;
CNC-4, 2-chloroethyl nitrosocarbamoylalanine; CNC-5, 2-chloroethylnitroso-
carbamoylglycylglycinemethylamide; DEP-isocyanate, diethyl-ethylphos-
phonale isocyanate; DEP-SG, diethyl-ethylphosphonate isocyanate glutathione
conjugate; DTNB, 5,5-dithiobis(2-nitrobenzoic acid); EDTA, ethylenediamino-
tetraacetic acid; fotemustine, (diethyl-[l-[3-(2-chloroethyl)-3-nitrosoureido]-
ethylphosphonate; F1A, flow injection analysis; 7-GT, y-glutamyl transpeptid-
ase; GSH, reduced glutathione; GSSG, oxidized glutathione; HECNU, N-(2-
chloroethyl)-/V'-(2-hydroxyethyl)-A'-nitrosourea: HEPES, JV-(2-hydroxyethyl)-
piperazine-/v"-(2-ethanesulfonic acid); HRP. horseradish peroxidase; LPO, lipid
peroxidation; MDA: maJondialdehyde; NAC, jV-acetyl-L-cysteine conjugate:
NBT, nitroblue tetrazolium; NEM, JV-ethyl-maJeimide: TBA, thiobarbituric
acid; TCA, trichloroacetic acid; TCNU, l-(2-chloroethyl)-3-[2-(dimethylami-
nosulfonyl)ethyl]-l-nitrosourea; TEA, triethanolamine; TNB, 5-thio-2-nitro-
benzoate.
these antioxidant enzymes are not likely to explain the
cytotoxic effects of fotemustine in hepatocytes. In conclu-
sion, it is proposed that the cytotoxicity of fotemustine in
rat hepatocytes is caused by rapid and extensive depletion
of GSH by DEP-isocyanate, a reactive decomposition
product of fotemustine, consequently hampering the endo-
genous protection against its own toxicity. Knowledge of
molecular mechanisms of the cytotoxicity of fotemustine
may contribute to a more rational design of selective
protection against toxic side-effects which occur upon
therapy of patients with fotemustine.
Introduction
Fotemustine is a DNA-alkylating 2-chloroethyl-substituted N-
nitrosourea (CENTJ*) (Figure 1) (1). The chemotherapeutic
drug is known to decompose rapidly into 2-chloroethyldiazo-
hydroxide and diethyl (l-ethyl)phosphonate (DEP)-isocyanate
(2). 2-Chloroethyldiazohydroxides can chloroethylate endo-
genous nucleophilic sites of macromolecules such as DNA
(3). Reactive isocyanates of CENUs have been suggested to
cause toxic effects (4,5) by carbamoylation of thiols and
primary amines of proteins and enzymes, such as chymotrypsin
(6), adenosine triphosphatase, acetylcholinesterase (7) and
GSSG-reductase (8). Different isocyanate-related toxicities
have meanwhile been reported. Genotoxic effects such as
chromosome aberrations, sister chromatid exchanges,
mutations and/or cancer are known (9). In rats and rabbits,
methyl isocyanate was shown to cause disturbed red blood cell
membrane functions, alveolar damage leading to pulmonary
oedema (7,10) and immunotoxicity with concomitant disturb-
ances in pulmonary functions (11). With n-butyl isocyanate,
severe histopathological lesions were observed in rat lungs (12).
In the treatment of cancer patients with fotemustine,
haematotoxicity (13) and reversible liver and renal toxicity (3)
occurred as toxic side-effects. However, in comparison to other
CENUs, such as 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU),
treatment with fotemustine is accompanied with a decreased
incidence and severity of side-effects. In vitro, it was found
that fotemustine, in contrast with BCNU, did not inhibit
endogenous enzymes such as GSSG-reductase (14,15), which
could be due to the sterical size of the diethyl (1-aminoethyl)
phosphonate (DEP) moiety of fotemustine. Data about the
molecular mechanisms of the toxic side-effects of fotemustine
are scarce and incomplete.
In vitro, fotemustine was only shown to decrease the activity
of thioredoxin reductase and ribonucleotide reductase (16). No
data are available about the nature of intermediate reactive
metabolites of fotemustine, involved in the inactivation of these
enzymes. In subcellular rat liver fractions, DEP-isocyanate, a
reactive decomposition product of fotemustine, was shown to
deplete GSH by conjugation (17). The excretion of GSH-
related metabolites in urine of rats treated with fotemustine
also points to involvement of GSH in the metabolic inactivation
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Fig. 1. Schematic overview of the metabolic pathways and mechanisms of action of fotemustine and its primary reactive metabolites; 2-
chloroethyldiazohydroxide, DEP-isocyanate and the GSH-conjugate of DEP-isocyanate (DEP-SG). I and II are decomposition products of fotemustine and
DEP-isocyanate.
of 2-chloroethyldiazohydroxide, a reactive DNA-alkylating
decomposition product of fotemustine (18) (Figure 1). Methyl
isocyanate, a reactive decomposition product of caracemide
was also shown to conjugate to GSH in vivo (19). Furthermore,
2-chloroethyl isocyanate, a reactive decomposition product of
BCNU has been demonstrated to form a toxic GSH-conjugate
(20). DEP-isocyanate might play a comparable role in the
undesired biological effects of fotemustine.
The primary aim of this study is to elucidate possible
mechanisms for the cytotoxic effects of fotemustine. For that
purpose, the metabolism and the cytotoxicity of fotemustine
were first investigated in freshly isolated rat hepatocytes. As
parameters for cytotoxicity, lactate dehydrogenase (LDH)-
leakage, lipid peroxidation (LPO), depletion of intracellular
GSH and formation of GSSG were investigated. The cyto-
toxicity of DEP-isocyanate and DEP-SG, the GSH-conjugate
of DEP-isocyanate (17) were also investigated. Furthermore,
the cytotoxicity of six 2-chloroethyl analogues of fotemustine
(Figure 2), which are devoid of carbamoylating potency due
to intramolecular cyclization and quenching of the generated
reactive isocyanate (21), were investigated. The LPO-inducing
capacity of fotemustine in rat liver microsomes and the effects
of fotemustine on various enzymes in cytosolic rat liver
fractions were also studied.
Materials and methods
Chemicals and enzymes
N-ethyl-maleimide (NEM), Tnton X-100, bovine serum albumin (BSA) and
GSSG reductase (Type III from bakers yeast) were obtained from Sigma (St
Louis, USA). Xanthine, xanthine oxidase, collagenase, glucose-6-phosphate,
glucose-6-phosphate dehydrogenase, NADH, NADP, sodium pyruvate, GSH
(98%) and GSSG (91%) were obtained from Boehringer (Mannheim,
Germany). Acetic acid, ammonium acetate, CaCl2, DMSO, ethylenediamino-
tetraacetic acid (EDTA), ethanol (100%), semicarbazide hydrochloride and
triethanolamine (TEA) were obtained from Baker (Deventer, The Netherlands).
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Fig. 2. Chemical structures of 2-chloroethyl derivatives. HECNU,
N-(2-chloroethyl)-yV'-<2-hydroxyethyl)-/V-nitrosourea; CNC-1,
2-chloroethylnitrosocarbamoyl alaninemethylamide, CNC-2, 2-chloroethyl
nitrosocarbamoyl glycylglycine; CNC-3, 2-chloroethyl nitrosocarbamoyl
alanylalanine; CNC-4, 2-chloroethyl nitrosocarbamoylalanine; CNC-5,
2-chloroethylnitrosocarbamoylglycylglycinemethylamide; R, N(H)-C(O)-
N(NOXCH2CH2C1).
2,4-pentanedione, pyrazole and trichloroacetic acid (TCA) were obtained from
Merck (Darmstadt, Germany). Bromotrichloromethane and thiobarbituric acid
(TBA) was obtained from Aldrich Chemicals (Steinheim, Germany). N-(2-
hydroxyethyl)piperazine-W-(2-ethanesulfonic acid) (HEPES) was obtained
from USB Corporation (Cleveland, Ohio, USA). Trypan blue was obtained
from BDH Chemicals LTD (Poole, England). o-Dianisidine was obtained
from Janssen Chimica (Beersse, Belgium).
Fotemustine (99.8%) was kindly supplied by Servier (Courbevoie, France).
Diethyl (1 -amidoethyl)phosphonate-glutathione conjugate (DEP-SG) was syn-
thesised from fotemustine and GSH and identified with 3IP-NMR and by
FAB-MS in glycerol and thioglycerol and by MIKE mass spectrometry as
recently descnbed elsewhere (17). Compounds I and II (Figure 1) were
synthesized and subsequently characterized with 3IP-NMR, 'H-NMR, EI-MS
and CI-MS as descnbed elsewhere (17).
Preparation of cytosolic and microsolic fractions of rat liver. Rat liver cytosol











Fotemustlne, molecular mechanisms and toxic effects in rat
differential centrifugation of homogenized rat livers as described by Jefcoate
(22). The cytosolic and microsomal fractions were stored at -80°C until use.
Incubations with rat liver cytosolic fractions
Rat liver cytosolic fractions (3.69 mg protein/ml) were preincubated with 0
or 1.0 mM fotemustine (1 h, 37°C) and contained 0.3% (v/v) ethanol. After
preincubation, superoxide dismutase (SOD), catalase, GSH-peroxidase, GSSG-
reductase and total GSH S-transferase activity were investigated in cytosolic
rat liver fractions.
Superoxide dismutase activity. Superoxide dismutase (SOD) activity in rat
liver cytosol was determined by the inhibition of nitroblue tetrazolium (NBT)
reduction by superoxide anion radicals (O^) according to the method of
Sazuka et at. (23). The reaction mixture (2.9 ml) contained 0.043 M Na2CO3
buffer (pH 10.2), 0.1 mM xanthine, 0.1 mM EDTA, 0.05 mg BSA/ml,
0.025 mM NBT and 36 |ig rat liver cytosolic protein. After 10 min of
preincubation at room temperature, the reaction was started with 75 |JJ xanthine
oxidase (0.05 U/ml). The incubation was carried out for 20 min at 25°C.
After addition of 0.2 mM CuCl2, the absorbance of the solution was measured
spectrophotometncally at 560 nm.
Catalase activity. The catalase activity in rat liver cytosol was measured as
described by Sazuka et al. (23) by determining the reduction of o-dianisidine
peroxidauon resulting from hydrogen peroxide (H2O2) and horseradish
peroxidase (HRP). The assay solution contained 120 |ig cytosolic rat liver
protein/ml and 0.45 mM hydrogen peroxide in a 0.1 M potassium phosphate
buffer (pH 7.0). Aliquots of 0.5 ml were removed after 30 and 60 s and added
to 2.0 ml of potassium phosphate buffer (50 mM, pH 7.0) containing 0.2 mg
o-dianiside/ml, 0.0125 mg HRP/ml and 0.081 mg NaNyml. After 10 min of
incubation at room temperature, 5 0 * (v/v) H2SO4 was added to stop the
reaction. The absorbance of the reaction medium was measured spectrophoto-
metricaJly at 530 nm.
GSH-peroxidase activity. The activity of GSH-peroxidase was measured
spectrophotometrically at 340 nm by following oxidation of NADPH in
cytosolic fractions in the presence of GSH and H2O2 as described by Paglia
and Valentine (24). The assay solution contained 360 |ig cytosolic rat liver
protein, 0.3 mM NADPH, 3.8 mM NaN3 (to inhibit catalase), 5 mM GSH,
70 \xM hydrogen peroxide and 2 U/ml yeast GSSG-reductase in a 50 mM
potassium phosphate buffer (pH 7.0). The reaction was initiated by the addition
of 10 |il of the hydrogen peroxide and measured spectrophotometricaJly at
340 nm. The final reaction volume of the incubation- medium was 2.0 ml.
GSSG-reductase activity. The activity of GSSG-reductase was measured
spectrophotometncally at 340 nm by following oxidation of NADPH in
cytosolic fractions in the presence of GSSG according to Worthington and
Rosemeyer (25). The assay solution contained 3.6 |ig cytosolic protein, 0.2 M
KCI, 1 mM EDTA, 1 mM GSSG and 0.1 M NADPH in a 0.1 M potassium
phosphate buffer (pH 7.0). The reaction was started by the addition of 10 ill
cytosolic rat liver fraction and measured spectrophotometncally. at 340 nm.
The final volume of the incubation medium was 2.0 ml.
GSH S-transferase activity. GSH S-transferase (GST) activity in rat liver
cytosol was measured as described by Habig et al. (26) using l-chloro-2,4-
dinitrobenzene (CDNB) as substrate. The final reaction mixture (1 ml)
contained 0.36 mg cytosolic protein, 1 mM GSH and 1 mM CDNB in
potassium phosphate buffer (0.1 M, pH 6.5). The reaction was started by the
addition of 10 |il of 100 times diluted cytosolic rat liver fraction and the
increase in absorbance was measured spectrophotometrically at 340 nm.
Incubations with rat liver microsomal fractions
Lipid peroxidation. Rat liver microsomal fractions (0.49 mg/ml protein) were
prcincubated with 0 or 1.0 mM fotemustine (1 h, 37°Q which contained 0.3%
(v/v) ethanol. Before and after preincubation, LPO was investigated in
the microsomal fractions by measuring malondialdehyde production with
thiobarbitunc acid (TBA) as described by Haenen et al. (27). All the incubation
mixtures were buffered with Tris-HCl (50 mM; pH 7.4) and contained
semicarbazide hydrochloride (3 mM), MgCI2 (3 mM), NADP (0.3 mM),
glucose-6-phosphate (3 mM) and glucose-6-phosphate dehydrogenase
(0.7 U/ml). A 0.2 ml aliquot of the microsomal incubation mixture was added
to a 0.375% (w/v) TBA, 15% (w/v) TCA in 0.25 M HC1 solution. After
heating for 30 min at 80°C and centrifugation for 15 min at 4°C, the
absorbance at 535 nm versus 600 nm in the supernatant was determined
spectrophotometrically.
Isolation of rat hepatocytes
Hepalocytcs were isolated from fasted male Wistar rats (200-220 g; Harland,
Zeist, The Netherlands) by collagenase perfusion of the liver as described
previously by Nagelkerke et al. (28). The preperfusion and perfusion solutions
were buffered at pH 7.4 and pH 7.6, respectively, with 10 mM HEPES. The
total time of the perfusion was -15-20 min. Aliquots of the freshly isolated
hepatocytes were immediately counted with a hemacytometer in 0.4% trypan
blue solution containing 0.9% NaCl. The viability of the cells isolated by this
method was always >90%.
Incubations with rat hepatocytes
The freshly isolated rat hepatocytes (10* cells/ml) were incubated with
(i) 800 |iM fotemustine, (ii) 0, 10, 20, 50, 100, 200 or 500 |lM fotemustine,
(iii) A'-{2-chloroethyl)-W-(2-hydroxyethyl)-A'-nitrosourea (HECNU), 2-chloro-
ethyl nitrosocarbamoyl alaninemethylamide (CNC-1), 2-chloroethyl nitroso-
carbamoyl glycylglycine (CNC-2), 2-chloroethyl nitrosocarbamoyl
alanylalanine (CNC-3), 2-chloroethyl nitrosocarbamoyl alanine (CNC-4) or
2-chloroethyl nitrosocarbamoyl glycylglycinemethylamide (CNC-5), BCNU
or fotemustine and with (iv) 500 |iM fotemustine or 500 liM DEP-SG.
At various timepoints after starting the respective incubations, samples
were taken for the determination of LDH-leakage, LPO and the concentrations
of GSH and GSSG. The total volume of all the incubation mixtures was 7 ml.
In order to dissolve the various compounds, the incubation mixtures contained
a minor concentration of ethanol (in all cases <0.3% (v/v)). All the incubations
were repeated at least three times at different days. For all the investigated
parameters, analysis was performed in duplicate.
Cytotoxicity assays
LDH-leakage. Samples of 0.5 ml were taken from the hepatocyte incubations
(10* cells/ml) and centrifuged (50 g; 4 min; 4°C). LDH-leakage was determined
in the supernatant fraction via NADH oxidation in the presence of sodium
pyruvate as previously described by van de Straat et al. (29). The final reaction
mixture contained 0.2 mM NADH and 0.5 mM sodium pyruvate in 50 mM
triethanolamine (TEA) buffer (pH 7.4). The enzymatic reaction was initiated
by the addition of 20 |il of the supernatant.
Lipid peroxidation. Samples of 0.5 ml were taken from the hepatocyte
incubations (106 cells/ml) and malondialdehyde (MDA) was determined as a
parameter for lipid peroxidation (LPO) as described above according to
Haenen et al.(21).
GSH and GSSG concentrations. Samples of 0.5 ml were taken from the
hepatocyte incubations (106 cells/ml) and centrifuged (50 g\ 4 min; 4°C).
Intracellular concentrations of GSH and GSSG were determined in the
resuspended cell pellets using the flow injection analysis (FIA) method
previously described by Redegeld et al. (30). Bnefly, total glutathione (GSH
plus GSSG) concentrations were determined via an enzymatic recycling
reaction of GSH in a chromogenic reaction with 5r5-dithiobis(2-nitroben2oic
acid) (DTNB), finally leading to the formation of 5-thio-2-nitrobenzoate
(TNB) with an absorption maximum at 412 nm (30). Oxidized glutathione
(GSSG) was determined analogously except that the reduced GSH was
first trapped through reaction with an excess M-ethylmaleimide (NEM).
Extracellular GSSG concentrations were determined in the supernatant after
addition of 8.6 uJ of 70% HC104, as previously described (30).
Metabolism of fotemustine and DEP-SG
Incubations of the freshly isolated rat hepatocytes (106 cells/ml, buffered with
HEPES (10 ml, pH 7.4)) with 2 mM fotemustine or 2 mM DEP-SG were
followed with time by 3IP-NMR. Relatively high concentrations of fotemustine
and DEP-SG (2 mM) were chosen to investigate their metabolism, because
the detection limits of both compounds in hepatocytes are ~250 |iM. The
incubations contained 1.5% albumin. Control incubations of fotemustine were
performed (2 mM) in HEPES buffer (10 mM, pH 7.4) without hepatocytes
and in the absence or the presence of albumin (1.5%). Samples of 4.8 ml
were taken from the incubation media at 0 and 180 min and measured
immediately with 3IP-NMR.
Phosphorus NMR
Proton-decoupled 3IP-NMR measurements were performed on a Bruker MSL
280 system (162.0 MHz, 10 mm dual, 3 IP- I 9F probe). The apparatus collected
20 scans/min over time periods of 5 min during the first hour of the incubations
and over time periods of 30 min thereafter. The maximal resolution of 3 IP-
NMR signals in freshly isolated rat hepatocytes was 0.05 p.p.m. Chemical
shifts may deviate by 0.08 p.p.m., due to small differences in pH (± 0.05)
and in composition of the hepatocyte solutions. The 3IP-NMR chemical shifts
are expressed in p.p.m., relative to the chemical shift of 85% H3PO4 (0 p.p.m.).
Data analyses
The experimental results were evaluated statistically using the Student's j-test
and were considered significant if P < 0.05 in at least three different
incubations performed on different days.
Results
Metabolism of fotemustine and DEP-SG in rat hepatocytes
Figure 3 shows 3I P-NMR spectra in freshly isolated rat
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Fig. 3. 3IP-NMR spectra of freshly isolated rat hepatocytes, 0 and 3 h after
starting incubations with 2 mM fotemustine (A) or 2 mM DEP-SG (B) and
31P-NMR spectra of an incubation mixtures of 2 mM fotemustine in HEPES
buffer in the presence of 1.5% albumin, after 3 h of incubation (C).
2 mM DEP-SG. After 3 h of incubation, fotemustine was
converted completely in these hepatocytes. Approximately
45% of fotemustine (s, 5 = 26.1 p.p.m.) converted into
compound II (s, 5 = 30.3 p.p.m.) (Figure 3A), previously
identified as a hydrolytic decomposition product of DEP-
isocyanate (17). Approximately 20% of fotemustine decom-
posed into compound I (s, 5 = 24.0 p.p.m.), the dechlorination
B)
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Fig. 4. LDH-leakage (A), intracellular GSH-levels (B), intra- plus
extracellular GSSG-levels (C) and LPO (D) in freshly isolated rat
hepatocytes upon incubation with 0 and 800 |iM fotemustine. • , Control
(extracellular); Q 800 nM fotemustine (extracellular); O, control
(intracellular); • , 800 |iM fotemustine (intracellular).
product of fotemustine (17). Moreover, ~35% of fotemustine
converted into a variety of products (Til), visible between 27.3
and 28.1 p.p.m. These products were also found to be formed
in incubations of fotemustine in HEPES buffer and albumin
(1.5%) without hepatocytes (Figure 3C).3IP-NMR spectra of
the conversion of fotemustine in HEPES buffer without
albumine and hepatocytes were completely similar to the
3IP-NMR spectra as shown recently (17).
In incubations in buffer without albumin, the products
between 27.3 and 28.1 p.p.m. (HI) (Figure 3C) were not
formed. During 3 h of incubation in rat hepatocytes, ~30% of
DEP-SG (d, 8 = 26.2 p.p.m.), the GSH-conjugate of DEP-
isocyanate, converted into compound II (s, 8 = 30.7 p.p.m.)
(Figure 3B), which was recently identified as a hydrolytic
decomposition product of DEP-isocyanate (17). Approximately
60% of the original DEP-SG remained stable in the hepatocytes
during 3 h of incubation. The remaining 10% of DEP-SG was
not recovered after 3 h of incubation. A minor quantity of
compound I (s, 8 = 24.2 p.p.m.), a byproduct in the synthesis
of DEP-SG (17), was visible during the whole time course of
the incubation (Figure 3B).
Extent and time-dependencey of cytotoxicity of fotemustine
To find out whether fotemustine was cytotoxic to freshly
isolated rat hepatocytes, the extent of LDH-leakage, lipid
peroxidation (LPO), depletion of GSH and the formation of
intra- and extracellular GSSG were first investigated upon
addition of a relatively high concentration of fotemustine.
Furthermore, the time dependency of the various toxicity
parameters was investigated.
Figure 4 shows the LDH-leakage (Figure 4A), intracellular
GSH-levels (Figure 4B), intracellular and extracellular GSSG-
levels (Figure 4C) and LPO (Figure 4D) in freshly isolated rat
hepatocytes incubated with 800 (iM fotemustine. The GSH-
level decreased rapidly and almost completely upon addition
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Fig. 5. LDH-leakage (A), intracellular GSH-levels (B), extracellular GSSG-
levels (C) and LPO (D) upon incubation of freshly isolated rat hepatocytes
with 0, 10, 20, 50, 100, 200 and 500 \iM fotemustine. LDH-leakage in
incubations with 10, 20 and 50 uM fotemustine are not shown because data
were not significantly different from the controls. GSSG formation in the
incubation with 10 |iM fotemustine is not significantly different from the
controls. LPO in the incubations with 10, 20 and 50 |iM fotemustine was
not significantly different from the controls. • , Control; X, 10 |iM
fotemustine, A, 20 |iM fotemustine; A, 50 jiM fotemustine; O, 100 |lM
fotemustine; • , 200 p_M fotemustine; • , 500 \iM fotemustine,
decreased rapidly to non-detectable concentrations (<3 (iM)
(Figure 4C), while the extracellular GSSG-levels increased
rapidly and significantly (Figure 4C). In subsequent experi-
ments, only the extracellular GSSG concentrations were
measured therefore. After 30 min of incubation, the extracellu-
lar levels of GSSG remained relatively stable (Figure 4C).
Significant LPO, measured as TBA-reactive material, was
observed after 30 min of incubation of the hepatocytes with
800 (JM fotemustine (Figure 4D). LPO seemed to precede the
fotemustine-induced LDH-leakage, which was observed only
45 min after starting the incubation of the hepatocytes with
fotemustine (Figure 4A and 4D). During the remaining time
course of the incubations both LPO (Figure 4D) and LDH-
leakage (Figure 4A) increased further.
Concentration dependency of the cytotoxicity of fotemustine
The concentration and time versus effect relationships of
fotemustine-induced LDH-leakage, LPO, depletion of GSH
and formation of GSSG were subsequently investigated in the
freshly isolated hepatocytes. Figure 5 shows the time course
of LDH-leakage (Figure 5A), intracellular GSH-levels (Figure
5B), extracellular GSSG-levels (Figure 5C) and LPO (Figure
5D) in rat hepatocytes incubated with different concentrations
of fotemustine. A concentration-dependent decrease of
intracellular GSH-levels was observed up to 180 min (Figure
5B). A concentration of 50 uM fotemustine caused a significant
decrease and concentrations of 200 ĴVl and 500 |iM fotemus-
tine caused a rapid and nearly complete exhaustion of the
GSH-levels in rat hepatocytes (Figure 5B). Below a fotemustine
concentration of 100 (iM, a concentration- and time-dependent
increase of extracellular GSSG-levels was observed (Figure







Fig. 6. LDH-leakage (A), intracellular GSH-levels (B), extracellular GSSG-
levels (C) and LPO (D) upon incubation of freshly isolated rat hepatocytes
with 500 yM fotemustine or 500 nM DEP-SG. • , Control; D, 500 uM
fotemustine; • , 500 uM DEP-SG.
increased only up to 120 min and remarkably the extent
of the increase declined with increasing concentrations of
fotemustine (Figure 5C).
No LDH-leakage nor LPO were observed upon treatment
of the hepatocytes with fotemustine up to 100 uM (Figure 5A
and 5D). Concentration dependent LPO and LDH-leakage
were observed upon treatment of the hepatocytes with concen-
trations of fotemustine >100 fiM (Figure 5A and 5D).
Cytotoxicity of DEP-SG
Figure 6 shows the time-dependency of LDH-leakage (Figure
6A), intracellular GSH-levels (Figure 6B), extracellular GSSG-
levels (Figure 6C) and LPO (Figure 6D) in rat hepatocytes
incubated either with 500 |iM DEP-SG, the GSH-conjugate
of DEP-isocyanate, or with 500 (iM fotemustine. At this
concentration, fotemustine induced LDH-leakage, LPO and a
depletion of intracellular GSH, while the extracellular GSSG-
levels in rat hepatocytes were increased, similar to the previous
observations (Figures 4 and 5). DEP-SG was less cytotoxic,
when measured as LDH-leakage and LPO. Nevertheless,
500 |iM DEP-SG caused a significant LDH-leakage and LPO
in the hepatocytes. LPO was already statistically significant
after 2 h of incubation with 500 yM DEP-SG (Figure 6D),
the LDH-leakage was significant only after 3 h of incubation,
however (Figure 6A). Thus, the LPO caused both by DEP-SG
and by fotemustine preceded the corresponding LDH-leakage.
A concentration of 500 uJVl DEP-SG also caused a significant
decrease of the intracellular GSH-levels in the rat hepatocytes.
Remarkably, extracellular GSSG-levels increased to a larger
extent upon incubation of the hepatocytes with DEP-SG
when compared to an equimolar concentration of fotemustine
(Figure 6C).
Administration of 250 ^M DEP-SG to the hepatocytes did
not cause LDH-leakage nor LPO, however, it did cause a
significant decrease of the intracellular GSH-levels and an














Fig. 7. LDH-leakage (A), intracellular GSH-levels (B), extracellular GSSG-
levels ( O and LPO (D) upon incubation of freshly isolated rat hepatocytes
with 1 mM fotemustine, BCNU and trie 2-chloroethyl analogues HECNU
and CNC-I, CNC-2, CNC-3, CNC-4 and CNC-5. The LDH-leakage, LPO
and GSSG-formation in incubatrons with HECNU and CNC-1, CNC-2,
CNC-3, CNC-4 and CNC-5 was not significantly different from the
controls. Therefore, only LDH-leakage, LPO and GSSG-formation upon
incubation with 1 mM HECNU is shown. The time-course of the GSH-
levels upon incubation with HECNU and CNC-1, CNC-2, CNC-3 and
CNC-5 was not significantly different. Therefore, only the GSH-levels upon
incubation with HECNU and CNC-4 are shown. • , Control; D, I mM
fotemustine; • , 1 mM BCNU; O, I mM HECNU; A, 1 mM CNC-4.
Cytotoxicity of BCNU and 2-chloroethyl analogues of fote-
mustine
Figure 7 shows the time-dependency of LDH-leakage (Figure
7A), intracellular GSH-levels (Figure 7B), extracellular GSSG-
levels (Figure 7C) and LPO (Figure 7D) in freshly isolated rat
hepatocytes incubated with HECNU and CNC-1, CNC-2,
CNC-3, CNC-4, CNC-5, BCNU and fotemustine at concentra-
tions of 1 mM. Similar to previous observations (Figures 4, 5
and 6), fotemustine caused LDH-leakage, LPO, GSH-depletion
and GSSG-formation. In the case of BCNU, the extent of
LDH-leakage and LPO were faster and higher than with
fotemustine, however, no significant differences were observed
in GSH-depletion (Figure 7A, 7B and 7D). The increase
of extracellular GSSG upon incubation with BCNU was
significantly lower than with fotemustine (Figure 7C). None
of the 2-chloroethyl analogues of fotemustine caused any
significant LDH-leakage, LPO or GSSG-formation. Except for
CNC-4, none of the 2-chloroethyl analogues significantly
decreased GSH-levels.
Effects of fotemustine on antioxidant enzymes in cytosolic rat
liver fractions
Table I shows the effects of fotemustine on SOD, catalase,
GSH-peroxidase, GSSG-reductase and GSH S-transferases, all
being cytosolic enzymes directly or indirectly involved in
cytoprotective antioxidant processes. No statistically significant
effects were observed of fotemustine on SOD, catalase, GSH-
peroxidase and GSSG-reductase nor on GSH S-transferases in
cytosolic rat liver fractions (Table I).
Table I. Effects of fotemustine on SOD, catalase, GSH-peroxidase, GSSG-
reductase and GSH S-transferases in non-induced cytosolic rat liver




















Table II. LPO, measured as





formation of TBA-reactive products, in rat liver





LPO is expressed as AA535 n x 1000 of TBA-reactive material and
corrected for the 0 h background values.
Fotemustine-induced LPO in microsomal rat liver fractions
The fotemustine-induced LPO in rat liver microsomal fractions,
measured as formation of TBA-reactive material, was also
investigated. No direct LPO was observed by fotemustine in
rat liver microsomal fractions measured (Table IT). Bromo-
trichloromethane, which was used as a positive control com-
pound for the experimental procedures, caused extensive LPO
in rat microsomes (data not shown).
Discussion
Therapy of cancer patients with fotemustine is sometimes
hampered by haemato- and lung toxicity (13) and by mild but
reversible renal- and liver toxicity (3). As yet, almost nothing
is known about the mechanisms of these side-effects of
fotemustine. This study is therefore aiming at the elucidation
of potential molecular mechanisms underlying the cytotoxic
properties of fotemustine.
Metabolism of fotemustine and DEP-SG in rat hepatocytes
The metabolism of fotemustine and DEP-SG, the GSH-conjug-
ate of DEP-isocyanate, was first investigated in hepatocytes to
find out whether the metabolic behaviour of both compounds
might explain their cytotoxicity. Fotemustine was found to be
metabolized in compounds I, II and II (Figures 1 and 3). Its
metabolic profile was qualitatively comparable to that observed
earlier, in vitro, in HEPES buffer and rat liver-S9 fractions (17)
and in vivo, in rats (Brakenhoff,J.P.G. et ai, in preparation).
In the hepatocytes, however, a much smaller fraction of
fotemustine decomposed into compound n, a hydrolytic
decomposition product of DEP-isocyanate (17). The latter
observation is likely due to albumin as can be deduced from
the 3IP-NMR spectrum of a control incubation (Figure 3C).
Reversible exchange of DEP-isocyanate with nucleophiles
present in albumin leads to continuous regeneration of DEP-
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of iso(thio)cyanates has been shown to occur in the case of
GSH-conjugates of benzyl- and allyl isothiocyanate (31) and
of methyl isocyanate conjugated to the amino group in the
terminal valine residue of haemoglobin (32) and thiols or
amines in other proteins (33).
The formation of compound II in the present incubations
with DEP-SG (Figure 3), indicates that DEP-isocyanate must
have been formed in the incubations with DEP-SG. Therefore,
DEP-isocyanate can be formed both from fotemustine and
from DEP-SG as shown in Figure 1. In freshly isolated rat
hepatocytes, DEP-SG was much less stable than in HEPES
buffer at the same temperature (this study, 17). This medium-
dependent difference in stability of DEP-SG can probably be
explained by the formation of adducts between DEP-isocyanate
and albumin or other proteins in hepatocytes. Approximately
10% of the original DEP-SG could not be recovered in the
hepatocytes with a 3IP-NMR spectrum taken after 3 h of
incubation. This fraction of DEP-SG is probably converted
into non-identified adducts to albumin or other proteins.
Time-dependency of the cytotoxicity of fotemustine
Firstly, the cytotoxic effects of a relatively high concentration
of fotemustine were investigated in rat hepatocytes (Figure 4).
A concentration of 800 (xM of fotemustine caused a significant
LDH-leakage 45 min after starting the incubations. The LDH-
leakage was preceded by LPO, which was measured as TBA-
reactive material and observed 30 min after starting the
incubations. The fotemustine-induced LPO was in turn pre-
ceded by extensive GSH-depletion, an extensive decrease of
intracellular GSSG and an increase of extracellular GSSG-
levels. The effects of fotemustine on GSH- and GSSG-levels
were already measurable 15 min after starting the incubations.
The rapid and extensive decrease of the intracellular GSH-
levels supports the ability of fotemustine to pass the cellular
membrane rapidly.
Chemically induced LPO in rat hepatocytes can be a cause
as well as a consequence of cell death (34). In the case of
fotemustine, LPO preceded LDH-leakage suggesting a causal
relationship with cell death (27). Extensive depletion of
intracellular GSH is known to enhance LPO because of a
hampered cellular protective antioxidant capacity against
radical damage (27,35). In the metabolism of fotemustine no
free radicals are formed (17,18). However, endogenous free
radicals formed after depletion of intracellular GSH (36) might
also contribute to the generation of LPO. Depletion of GSH
by fotemustine is most likely caused by DEP-isocyanate,
a reactive decomposition product of fotemustine (17). In
incubations of fotemustine with hepatocytes, DEP-isocyanate
is indeed formed as can be deduced from the formation of
compound n, a known hydrolytic decomposition product of
DEP-isocyanate (17,18) (Figure 3).
Concentration-dependency of the cytotoxicity of fotemustine
Fotemustine concentration versus effect relationships were also
investigated in the hepatocytes. Upon exposure of hepatocytes
to fotemustine in concentrations <200 u,M, no LDH-leakage
nor LPO were observed, despite the fact that a significant
concentration-dependent decrease in GSH-levels and increase
in GSSG-levels were observed. Obviously, the cellular protec-
tion against the cytotoxicity of fotemustine is sufficient as
long as sufficient GSH is present. Fotemustine concentrations
>200 (iM were cytotoxic to the rat hepatocytes. GSH is known
to be the major cellular thiol-compound protecting proteins
from covalent binding to reactive intermediates and from
oxidative damage (37,38). Covalent binding of reactive inter-
mediates to protein-thiols in calcium translocases located in
the plasma membrane, microsomes or mitochondria is known
to lead to a disturbed cellular calcium homeostasis (38-^40).
Depletion of intracellular calcium is known to cause an increase
of cellular peroxides, ultimately leading to LPO (41). In
principle, LPO might also be due to inhibitory effects on
thioredoxin reductase, an enzyme involved in various anti-
oxidant processes (16).
The GSH-depletion observed upon incubation of rat hepato-
cytes with fotemustine can be explained by conjugation of
GSH to DEP-isocyanate. Other metabolic pathways of DEP-
isocyanate apparently occur only after complete depletion of
GSH. The observed GSH-depletion, however, might also be
explained by oxidation of GSH to GSSG, chemically or as
a result of GSH-peroxidase- or GSSG-reductase-mediated
reduction of hydroperoxides (42). GSSG is known to be
efficiently transported out of liver cells by an ATP-dependent
translocase and is therefore measured extracellularly (39).
Cytotoxicity of DEP-SG
In order to investigate the possible role of the reactive DEP-
isocyanate in the cytotoxicity induced by fotemustine, the
various cytotoxicity parameters were also determined in
hepatocytes incubated with synthetic DEP-SG, the GSH-
conjugate of DEP-isocyanate and a precursor of DEP-iso-
cyanate.
The cytotoxicity of DEP-SG was found to be significantly
lower than that of fotemustine (Figure 6). The fact that in the
case of DEP-SG lower amounts of compound II, a hydrolysis
product of DEP-isocyanate, were detected than in the case
of fotemustine, suggests that lower concentrations of DEP-
isocyanate have been present in the incubations with DEP-
SG. This might explain the lower toxicity of DEP-SG when
compared to fotemustine. The observed cytotoxicity of DEP-
SG supports our earlier suggestion that GSH-conjugation of
DEP-isocyanate is only a temporary mechanism of protection
against the toxicity of fotemustine due to apparent reversibility
of the GSH-conjugation reaction with DEP-isocyanate (17).
In incubation mixtures with DEP-SG, the initial intracellular
GSH-level was found to be significantly higher than in incuba-
tion mixtures with fotemustine. However, control experiments
revealed that with the FIA method applied, GSH also con-
jugated to DEP-isocyanate and/or the GSH liberated from DEP-
SG could be measured (data not shown). As a consequence, the
decrease of intracellular GSH-levels observed in incubations
with fotemustine and DEP-SG is essentially reflecting the
decrease of the sum of intracellular GSH and intracellular
DEP-SG or GSH derived from DEP-SG. This observation
supports the suggestion that DEP-SG, containing a lipophilic
diethyl (1-amidoethyl) phosphonate side chain, rapidly passes
cellular membranes (43). GSH-conjugates are known to pass
cellular membranes via different mechanisms of active trans-
port (44). Decreasing amounts of GSH in incubations with
DEP-SG or fotemustine (Figure 6B) can be explained by
oxidation into GSSG or by further metabolism of DEP-SG.
For example, GSH-conjugates are known to be cleaved by
y-glutamyl transpeptidase (y-GT), a hydrolytic enzyme located
mainly in the hepatic cell membranes (44).
Remarkably, in hepatocytes incubated with DEP-SG, the
increase of GSSG-levels was higher than in similar incubations
with fotemustine. The latter is probably due to an almost












incubation with fotemustine but not upon incubation with
DEP-SG (Figure 6B). GSH-conjugates of both methyl and
2-chloroethylisocyanate are potent inhibitors of GSSG-reduc-
tase, which might also lead to increased levels of GSSG
(45,46). DEP-SG-induced formation of GSSG, however, is
difficult to explain by this phenomenon because DEP-isocyan-
ate, its reactive decomposition product, was shown to be devoid
of inhibiting properties towards GSSG-reductase (this study).
Cytotoxicity of BCNU and 2-chloroethyl analogues of fote-
mustine
In the present study, BCNU appeared to be more cytotoxic
than fotemustine, probably because of a higher reactivity
of 2-chloroethylisocyanate when compared to that of DEP-
isocyanate. GSSG formation, however, was significantly lower
in incubations with BCNU than with fotemustine. Because the
inhibitory activity of BCNU towards GSSG-reductase is higher
when compared to that of fotemustine (2), a higher formation
of GSSG was expected in the case of BCNU. The fact that
the reverse was observed may be explained by a more rapid
and complete depletion of GSH in incubations with BCNU.
The present study has shown that only fotemustine and
BCNU, which are both known to form reactive isocyanates
(17,21,47), cause GSH-depletion, GSSG-formation and cyto-
toxicity in hepatocytes. In contrast, the 2-chloroethyl analogues
of fotemustine, HECNU and CNC-1, CNC-2, CNC-3 and
CNC-5, which have no carbamoylating potency as a result of
intramolecular quenching of the reactive isocyanate (21), were
found not to be cytotoxic in the present study. This confirms
our suggestion that reactive isocyanates are mainly responsible
for the observed GSH-depletion and cytotoxicity with CENUs
in rat hepatocytes. The fact that CNC-4, in contrast to the
other investigated 2-chloroethyl analogues, decreased the
intracellular GSH-levels in hepatocytes is reasonable because
the isocyanate moiety of CNC^l cannot be inactivated by
intra-molecular amide formation (21). The reactive 2-chloro-
ethyldiazohydroxides which can be formed from fotemustine,
BCNU and from HECNU and CNC-l-CNC-5 are apparently
inferior in this regard. Studies on the involvement of 2-
chloroethyldiazohydroxides in undesired effects are very
scarce. Only the bone-marrow toxicity upon therapy with
CENUs has been related to 2-chloroethylation of endogenous
nucleophilic sites (48). Relationships between the carbamoylat-
ing capacity of CENUs and toxic side-effects, however, have
been well documented (48-50). The difference in severity of
toxic side-effects of BCNU and HECNU was suggested to be
caused by the difference in carbamoylating capacity of both
CENUs (14).
Effects of fotemustine in rat liver cytosolic and microsomal
fractions
To find out whether fotemustine or its reactive decomposition
product DEP-isocyanate cause peroxidation of cellular mem-
branes, we investigated LPO as well as possible inhibitory
effects of both compounds on enzymes involved in antioxidant
processes.
In contrast to the observations in hepatocytes, in rat liver
microsomes no direct LPO was observed with fotemustine.
Obviously, as with other CENUs, no radicals are formed
during metabolism or chemical decomposition of fotemustine.
Furthermore, no inhibitory effects of fotemustine were
observed on SOD, catalase, GSH-peroxidase and GSSG-
reductase nor on GSH S-transferases in cytosolic rat liver
fractions. This suggests that the LPO observed upon incubation
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of hepatocytes with fotemustine is not likely explained by
inhibitory effects of fotemustine on the above-mentioned
antioxidant enzymes. Inhibitory effects on GSSG-reductase
have been described for BCNU (47,51) and other CENUs such
as chlorozotocin,. CCNU and TCNU (52). This inhibiting
activity was shown to be related to the carbamoylating proper-
ties of their reactive isocyanate decomposition products (52).
In line with the present study, Boutin et al. (15) found that
fotemustine did not inhibit GSSG-reductase. It has been
suggested that this is due to the size of the diethyl (1-
amidoethyl) phosphonate (DEP)-moiety of fotemustine. BCNU
and HECNU were previously reported to inhibit GSH S-
transferase activity in bone marrow but not in other tissues
(48). No inhibitory effects of CENUs on GSH-peroxidase,
SOD or catalase are known.
The observed absence of fotemustine-induced LPO in rat
liver microsomes and the absence of inhibitory effects of
fotemustine on cytosolic antioxidant enzymes suggest that the
fotemustine-induced LPO occurs at the mitochondrial level.
In line with this suggestion, methylisocyanate was recently
shown to cause LPO in rat liver mitochondria (53), while
2-chloroethylisocyanate, a reactive decomposition product of
BCNU, was shown to cause LPO in rat hepatocytes by
depletion of mitochondrial GSH (54).
In summary, fotemustine was found to cause concentration-
and time-dependent cytotoxic effects in rat hepatocytes. GSH-
depletion and GSSG-formation were first observed, sub-
sequently LPO and finally cell death, measured as LDH-
leakage. A number of 2-chloroethyl analogues of fotemustine,
which in contrast to fotemustine, have no carbamoylating
capacity due to intramolecular quenching of their reactive
isocyanate decomposition products, were not toxic to rat
hepatocytes. This supports the suggestion that the toxicity of
fotemustine is caused by DEP-isocyanate. Fotemustine did not
induce LPO in rat liver microsomes, nor did fotemustine affect
the rat liver cytosolic antioxidant enzymes SOD, catalase,
GSH-peroxidase, GSSG-reductase and GSH S-transferases.
These observations support the suggestion that the fotemustine-
induced LPO in hepatocytes is most likely a result of rapid
and extensive depletion of GSH by DEP-isocyanate. GSH-
conjugation of DEP-isocyanate is apparently not an effective
mechanism of detoxification because DEP-SG, the GSH-
conjugate of DEP-isocyanate was also toxic to the rat hepato-
cytes.
GSH-depletion by DEP-isocyanate and concomitant
oxidative cell damage may also play a role in the toxic side-
effects observed in patients, such as haemato, liver and renal
toxicity (BrakenhoffJ.P.G. et al. the present study can be
helpful in explaining these toxic side effects as well as in the
design of chemoprotective tools (55).
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